Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.43 |
| ▸ | CFTR | P13569 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30599566 | 1.00 | ALDH1A1 (0.43) | ALDH1A1HSD17B10CFTRCA12CA1 | |
| SCHEMBL5886481 | 0.85 | ALDH1A1 (0.43) | ALDH1A1HSD17B10CFTRCA12CA1 | |
| SCHEMBL30724527 | 0.85 | ALDH1A1 (0.43) | ALDH1A1HSD17B10CFTRCA12CA1 | |
| SCHEMBL8187328 | 0.85 | ALDH1A1 (0.43) | ALDH1A1HSD17B10CFTRCA12CA1 | |
| SCHEMBL3518044 | 0.84 | CA12 (0.48) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL30108114 | 0.84 | ALDH1A1 (0.42) | ALDH1A1HSD17B10CFTRCA12CA1 | |
| SCHEMBL26110954 | 0.84 | ALDH1A1 (0.42) | ALDH1A1HSD17B10CFTRCA12CA1 | |
| SCHEMBL543938 | 0.84 | CISD2 (0.43) | ALDH1A1HSD17B10CFTRCA12CA1 | |
| SCHEMBL27432587 | 0.84 | CA12 (0.46) | ALDH1A1HSD17B10CFTRCA12CA1 | |
| SCHEMBL29562833 | 0.82 | ABL1 (0.47) | ALDH1A1HSD17B10CFTRCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595239-B2 | Substituted isoxazoline derivatives | BASF SE (DE) | 2026-04-07 | — | — | US | disclosed |
| EP-4291551-B1 | SUBSTITUTED ISOXAZOLINE DERIVATIVES | BASF SE (DE) | 2025-08-13 | — | — | EP | disclosed |
| US-20240140917-A1 | SUBSTITUTED ISOXAZOLINE DERIVATIVES | BASF SE (DE) | 2024-05-02 | — | — | US | disclosed |
| US-11858927-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| US-11858927-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| CN-116888101-A | Substituted isoxazoline derivatives | 巴斯夫欧洲公司 | 2023-10-13 | — | — | CN | disclosed |
| US-11731968-B2 | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2023-08-22 | — | — | US | disclosed |
| US-11731968-B2 | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2023-08-22 | — | — | US | disclosed |
| US-11731968-B2 | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2023-08-22 | — | — | US | disclosed |
| US-11634409-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | ARRAY BIOPHARMA INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| WO-2009137391-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137391-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009111278-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111279-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111280-A1 | N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111277-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634409-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | BRAF, NRAS, RAF1 | ALDH1A1 1626/4885HSD17B10 3960/4885CFTR 775/4885 |
| US-12595239-B2 | Substituted isoxazoline derivatives | CBR3, ADRA2C, CYP4Z1 | ALDH1A1 854/4885HSD17B10 1825/4885CFTR 2743/4885 |
| US-20240140917-A1 | SUBSTITUTED ISOXAZOLINE DERIVATIVES | CYP4X1, PRDX5, PRDX1 | ALDH1A1 1168/4885HSD17B10 3183/4885CFTR 3331/4885 |
| US-11731968-B2 | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAP4K1, MAP4K4 | ALDH1A1 4054/4885HSD17B10 839/4885CFTR 3376/4885 |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | ALDH1A1 915/4885HSD17B10 2282/4885CFTR 394/4885 |
| US-11858927-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAP3K4, MAP4K1 | ALDH1A1 2857/4885HSD17B10 1784/4885CFTR 3127/4885 |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | ALDH1A1 2787/4885HSD17B10 3023/4885CFTR 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.